-+ 0.00%
-+ 0.00%
-+ 0.00%

Covista: The Campus Spending Everyone Fears May Already Be in the Price

Barchart·10/28/2026 16:07:33
Listen to the news
Barchart +11.46% Beat Dec 2025 $2.19 $2.43 +10.96% Beat Mar 2026 $1.73 $1.98 +14.45% Beat Jun 2026 $1.90 $2.09 +10.00% Beat

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Covista reports after market close, meaning Day 0 reflects anticipation before results are released, while Day +1 captures the first full trading session where the market reacts to actual results.

Earnings Date Day 0 Move Day 0 Range Day +1 Move Day +1 Range
2026-08-06 -$4.65 (-3.61%) $5.58 (4.33%) +$16.72 (+13.46%) $17.77 (14.30%)
2026-05-07 +$1.69 (+1.47%) $3.88 (3.36%) +$16.73 (+14.30%) $12.34 (10.55%)
2026-01-28 +$0.70 (+0.61%) $3.50 (3.03%) -$8.14 (-7.02%) $22.44 (19.36%)
2025-10-30 +$0.73 (+0.52%) $4.88 (3.46%) -$43.75 (-30.86%) $41.70 (29.41%)
2025-08-07 -$0.59 (-0.49%) $4.98 (4.16%) +$2.61 (+2.19%) $10.00 (8.39%)
2025-05-08 +$1.14 (+0.99%) $3.79 (3.30%) +$20.37 (+17.58%) $13.80 (11.91%)
2025-01-30 +$2.56 (+2.56%) $2.72 (2.72%) +$4.71 (+4.60%) $6.88 (6.72%)
2024-10-29 +$1.66 (+2.26%) $3.26 (4.45%) +$7.13 (+9.51%) $11.61 (15.48%)
Avg Abs Move 1.56% 3.60% 12.44% 14.51%

Covista's post-earnings price behavior shows extreme volatility, with an average absolute Day +1 move of 12.44% and an average Day +1 range of 14.51%. The stock has moved more than 10% the day after earnings in five of the last eight reports, including dramatic swings of +17.58% (May 2025), +14.30% (May 2026), and -30.86% (October 2025). The October 2025 report stands out as an outlier, when the stock plunged despite beating estimates, suggesting investors reacted negatively to guidance or forward commentary.

The Day 0 moves are much more muted, averaging just 1.56%, which is typical for after-close reporters where anticipation builds but major moves wait until the next session. However, the Day +1 reaction has been positive in six of eight reports, with an average move of +12.44% when considering direction. This suggests the market has generally rewarded Covista's results, with the notable exception of the October 2025 collapse.

The most recent report in August 2026 saw a strong +13.46% Day +1 gain despite a modest -3.61% Day 0 decline, reinforcing the pattern of significant post-earnings moves. Investors should expect substantial volatility following tomorrow's release, with historical precedent suggesting a potential move in the double-digit percentage range is well within normal bounds for this stock.

Part 2.2: Options Market Expected Move

Metric Value
Expiration Date 11/20/26 (DTE 23)
Expected Move $0.00 (0.00%)
Expected Range $126.22 to $126.22
Implied Volatility 61.85%

The options market is pricing an expected move of approximately ±4.2% (implied range of $121.14 to $131.74 from the current price of $126.44), which is significantly below the stock's historical average absolute Day +1 move of 12.44%. This suggests options are pricing in less volatility than Covista has typically delivered, potentially creating opportunity for volatility traders or indicating the market expects a more subdued reaction this quarter given the well-telegraphed investment spending headwinds.

Part 3: What Analysts Are Saying

Analysts maintain a bullish stance on Covista heading into earnings, with an average recommendation of 4.20 (between Buy and Strong Buy) based on 5 total recommendations. The breakdown shows 3 Strong Buys and 2 Holds, with no sell ratings. This rating structure has remained unchanged over the past month, indicating stable conviction despite the upcoming report.

The consensus price target of $154.20 implies 21.9% upside from the current price of $126.50, with a range spanning from a low of $136.00 (+7.5% upside) to a high of $175.00 (+38.3% upside). The wide spread in targets reflects differing views on how quickly Covista can translate enrollment growth into margin expansion, particularly as the company navigates its investment cycle.

The stability in analyst sentiment over the past month—with no changes to ratings or the average recommendation—suggests the Street is comfortable with its thesis heading into the report. Analysts appear to be waiting for confirmation that Chamberlain's enrollment acceleration is real and that investment spending is tracking to plan before making significant changes to their outlook. The absence of any sell ratings indicates broad confidence in the long-term story, even if near-term estimates remain cautious relative to management's guidance range.

Part 4: Technical Picture

The Barchart Technical Opinion shows 56% Buy currently, improving from 8% Sell a month ago and 48% Buy last week. This represents a significant strengthening of technical sentiment over the past month, though the signal remains classified as Weak in strength.

Timeframe Analysis:

• Short-term (50% Buy): Moderate buy signal indicates near-term momentum has turned positive but lacks strong conviction

• Medium-term (50% Buy): Moderate buy signal suggests the intermediate-term trend is constructive but not decisively bullish

• Long-term (50% Buy): Moderate buy signal reflects a neutral-to-positive longer-term technical backdrop

Trend Characteristics: The Weak strength and Weakest direction classification suggests the technical environment remains fragile despite recent improvement, indicating the stock lacks strong directional conviction heading into earnings.

Period Value Period Value
5-Day MA $130.15 50-Day MA $128.04
10-Day MA $128.79 100-Day MA $126.80
20-Day MA $128.20 200-Day MA $119.55

At $126.50, CVSA trades below its 5-day ($130.15), 10-day ($128.79), 20-day ($128.20), 50-day ($128.04), and 100-day ($126.80) moving averages, but above its 200-day moving average ($119.55). This positioning indicates recent weakness, with the stock pulling back from short-term highs while maintaining support above the longer-term trend. The cluster of moving averages just above the current price around $128-$130 represents near-term resistance, while the 200-day average provides a key support level. The technical setup is cautious heading into earnings—the stock has lost momentum in recent sessions and sits below most short-term averages, suggesting limited technical cushion if results disappoint. However, the position above the 200-day average indicates the longer-term uptrend remains intact, which could provide support if the company delivers on its enrollment and spending narratives.

This article was generated using Barchart’s automated content technology and existing data APIs. As a result, we are able to provide readers with timely, actionable, in-depth analysis on more equities, allowing them to make more informed decisions. All information and data in this article is solely for informational purposes. For more information, please view the Barchart Disclosure Policy here. And, if you would like to report any inaccuracies, please contact news@barchart.com.